Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post by UEG Journal on LinkedIn, adding:
“We thank UEG Journal for publishing this open-access review on AI-assisted transcriptomic signatures in pancreatic ductal adenocarcinoma, and we acknowledge the collective work of the authors: Brice Chanez, Matthieu Delaye, Nicolas Fraunhoffer Ph.D., Juan Iovanna and Cindy NEUZILLET.
The article provides a clear and rigorous overview of how transcriptomic predictors are contributing to more informed chemotherapy decision-making in PDAC, integrating biological insight with clinically applicable tools.”
Quoting UEG Journal‘s post:
“AI-assisted transcriptomic signatures redefine chemotherapy decisions in pancreatic cancer
This open-access review synthesizes how transcriptomic signatures are transforming chemotherapy selection in pancreatic ductal adenocarcinoma (PDAC), moving the field beyond empirical treatment choices toward true precision medicine
Key takeaways:
- Chemotherapy remains the backbone of PDAC treatment, but responses and toxicity vary widely
- Patient-derived organoids and molecular subtypes improved biological insight, yet remain limited for routine decision-making
- Transcriptomic predictors offer practical, biopsy-compatible tools to guide therapy
- GemPred identifies patients likely to benefit from adjuvant gemcitabine
- GemCore extends prediction to metastatic disease and small biopsies
- Pancreas-View, an AI-assisted platform, integrates multi-drug sensitivity (gemcitabine + all FOLFIRINOX components)
- Predicted drug sensitivity consistently correlates with improved survival across large cohorts and clinical trials
These signatures open the door to better first-line choices, treatment de-escalation, and early identification of multidrug-resistant tumors, supporting a new framework for personalized chemotherapy in PDAC.”
Title: Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures
Authors: Brice Chanez, Matthieu Delaye, Nicolas Fraunhoffer, Juan Iovanna, Cindy Neuzillet, Nelson Dusetti
More posts featuring Nelson Dusetti on OncoDaily.